OTLK - NASDAQ

Outlook Therapeutics, Inc.

OTLK·NASDAQ

$1.58

-0.94%

HealthcareBiotechnology

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$70.18M

EPS-1.7900

P/E Ratio-0.88

Earnings Date02/13/2026

otlk

Other Financing Activities

Last Annual Value

44984.98B

3-Year CAGR

48407%

5-Year CAGR

3206%

10-Year CAGR

539%

Adjust for Inflation

Outlook Therapeutics, Inc. Competitors Analysis of Other Financing Activities

OTLK · NASDAQ

Company	Other Financing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Outlook Therapeutics, Inc. NASDAQ:OTLK	44984.98B	N/A	2528.5%	N/A
Spruce Biosciences, Inc. NASDAQ:SPRB	-4.53M	N/A	N/A	N/A
OS Therapies Incorporated NYSE:OSTX	31.25M	N/A	215.5%	N/A
Century Therapeutics, Inc. NASDAQ:IPSC	0.00	N/A	N/A	N/A
Equillium, Inc. NASDAQ:EQ	0.00	N/A	N/A	N/A
MiNK Therapeutics, Inc. NASDAQ:INKT	14.71B	5831.7%	3865.4%	N/A
Aligos Therapeutics, Inc. NASDAQ:ALGS	0.00	N/A	N/A	N/A
Relmada Therapeutics, Inc. NASDAQ:RLMD	-73.02K	N/A	N/A	N/A
Sutro Biopharma, Inc. NASDAQ:STRO	-332.00K	N/A	N/A	N/A
CEL-SCI Corporation AMEX:CVM	-2.37M	N/A	N/A	N/A
Cue Biopharma, Inc. NASDAQ:CUE	0.00	N/A	N/A	N/A

Outlook Therapeutics, Inc. Fair Value Envelope

OTLK · NASDAQ

Our analysis suggests that OTLK has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.58, this represents a potential HIDDEN relative to our calculated worth for Outlook Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.58

Related Guides

Blog Categories

Continue your OTLK research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.